Lung cancer: current therapies and new targeted treatments

The Lancet

Volumn 389, Issue 10066, 2017, Pages 299-311

  Hirsch, Fred R ^a,b   Scagliotti, Giorgio V ^c   Mulshine, James L ^d   Kwon, Regina ^e   Curran, Walter J ^f   Wu, Yi Long ^g   Paz Ares, Luis ^h  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b International Association for the Study of Lung Cancer   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER SCREENING; CANCER STAGING; EARLY CANCER; GENE MUTATION; HUMAN; LUNG CANCER; MAINTENANCE THERAPY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; SMOKING CESSATION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THORAX RADIOGRAPHY; CARCINOMA, NON-SMALL-CELL LUNG; EARLY CANCER DIAGNOSIS; GENETICS; IMMUNOTHERAPY; LUNG NEOPLASMS; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; EARLY DETECTION OF CANCER; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MUTATION; SURVIVAL RATE;

EID: 84994087188     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30958-8     Document Type: Review

References (152)

1. 1 Ferlay, J, Soerjomataram, I, Dikshit, R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. 2 American Cancer Society. Cancer facts & figures 2015, 2015, American Cancer Society, Atlanta http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf (accessed Dec 31, 2015).
3. 3 Aberle, DR, Adams, AM, Berg, CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (2011), 395–409.
4. 4 Horeweg, N, van Rosmalen, J, Heuvelmans, MA, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a pre-specified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol 15 (2014), 1332–1341.
5. 5 Field, JK, Duffy, SW, Baldwin, DR, et al. UK lung cancer RCT pilot screening trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax 71 (2015), 161–170.
6. 6 Henschke, C, Yip, R, Yankelevitz, DF, et al. Definition of a positive test result in computed tomography screening for lung cancer: a cohort study. Ann Intern Med 158 (2013), 246–252.
7. 7 Kazerooni, EA, Armstrong, MR, Amorosa, JK, et al. ACR CT accreditation program and the lung cancer screening program designation. J Am Coll Radiol 12 (2015), 38–42.
8. 8 Pinsky, PF, Gierada, DS, Black, W, et al. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. Ann Intern Med 162 (2015), 485–591.
9. 9 Frank, L, Christodoulou, E, Kazerooni, EA, Radiation risk of lung cancer screening. Semin Respir Crit Care Med 34 (2013), 738–747.
10. 10 Yoshizawa, A, Motoi, N, Riely, GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 24 (2011), 653–664.
11. 11 Yankelevitz, DF, Yip, R, Smith, JP, et al. CT screening for lung cancer: nonsolid nodules in baseline and annual repeat rounds. Radiology 277 (2015), 555–564.
12. 12 Mulshine, JL, D'Amico, A, Issues with implementing a high-quality lung cancer screening program. CA Cancer J Clin 64 (2014), 352–363.
13. 13 Flores, R, Bauer, T, Aye, R, et al. Balancing curability and unnecessary surgery in the context of computed tomography screening for lung cancer. J Thorac Cardiovasc Surg 147 (2014), 1619–1626.
14. 14 Villanti, AC, Jiang, Y, Abrams, DB, Pyenson, BS, A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PLoS One, 8, 2013, e71379.
15. 15 Ostroff, JS, Copeland, A, Borderud, SP, Li, Y, Shelley, DR, Henschke, CI, Readiness of lung cancer screening sites to deliver smoking cessation treatment: current practices, organizational priority, and perceived barriers. Nicotine Tob Res 18 (2015), 1067–1075.
16. 16 Zhou, QH, Fan, YG, Bu, H, et al. China national lung cancer screening guideline with low-dose computed tomography (2015 version). Thorac Cancer 6 (2015), 812–818.
17. 17 Canadian Task Force on Preventive Health Care. Recommendations on screening for lung cancer. CMAJ 188 (2016), 425–432.
18. 18 Bailar, JC, Screening for lung cancer—where are we now?. Am Rev Respir Dis 130 (1984), 541–542.
19. 19 Vansteenkiste, J, Crinò, L, Dooms, C, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 25 (2014), 1462–1474.
20. 20 Goldstraw, P, Chansky, K, Crowley, J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11 (2016), 39–51.
21. 21 Cao, C, Manganas, C, Ang, SC, Peeceeyen, S, Yan, TD, Video-assisted thoracic surgery versus open thoracotomy for non-small cell lung cancer: a meta-analysis of propensity score-matched patients. Interact Cardiovasc Thorac Surg 16 (2013), 244–249.
22. 22 Pignon, JP, Tribodet, H, Scagliotti, GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis from the LACE Collaborative Group. J Clin Oncol 26 (2008), 3552–3559.
23. 23 NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 383 (2014), 1561–1571.
24. 24 Kelly, K, Altorki, NK, Eberhardt, WE, et al. Adjuvant erlotinib versus placebo in patients with stage IB–IIIA non-small cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol 33 (2015), 4007–4014.
25. 25 Hirsch, FR, Bunn, PA Jr, Adjuvant TKIs in NSCLC: what can we learn from RADIANT?. Nat Rev Clin Oncol 12 (2015), 689–690.
26. 26 Wakelee HA, Dahlberg SE, Keller SM, et-al. Randomized phase III trial of adjuvant chemotherapy with or without bevacizumab in resected non-small cell lung cancer (NSCLC): Results of E1505. World Conference on Lung Cancer; Denver, CO, USA; Sept 6–9, 2015. Abstract 1608.
27. 27 Goss, GD, O'Callaghan, C, Lorimer, I, et al. Gefitinib versus placebo in completely resected non-small cell lung cancer; result of the NCIC-CTG BR 19 study. J Clin Oncol 31 (2013), 3320–3326.
28. 28 National Cancer Institute. ALCHEMIST (Adjuvant Lung Cancer Enhancement Marker Identification and Sequencing Trials). http//www.cancer.gov/types/lung/research/alchemist (accessed March 25, 2016).
29. 29 Timmerman, R, Paulus, R, Galvin, J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303 (2010), 1070–1076.
30. 30 Fakiris, AJ, McGarry, RC, Yiannoutsos, CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75 (2009), 677–682.
31. 31 Curran, WJ Jr, Paulus, R, Langer, CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103 (2011), 1452–1460.
32. 32 Auperin, A, Pechoux, C, Rolland, E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28 (2010), 2181–2190.
33. 33 Bradley, J, Paulus, R, Komaki, R, et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal radiotherapy with concurrent and consolidation carboplatin/paclitaxel with or without cetuximab for patients with stage IIIA/IIIB non-small cell lung cancer: RTOG 0617. Lancet Oncol 16 (2015), 187–199.
34. 34 Senan, S, Brade, A, Wang, LH, et al. PROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 34 (2016), 953–962.
35. 35 Tsao, AS, Scagliotti, GV, Bunn, PA Jr, et al. Scientific advances in lung cancer 2015. J Thorac Oncol 11 (2016), 613–638.
36. 36 Tan, DSW, Yom, SS, Tsao, MS, et al. The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation positive NSCLC: status in 2016. J Thorac Oncol 11 (2016), 946–963.
37. 37 Rosell, R, Carcereny, E, Gervais, R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13 (2012), 239–246.
38. 38 Park, K, Tan, E-H, O'Byrne, K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17 (2016), 577–589.
39. 39 Jänne, PA, Yang, JC, Kim, DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372 (2015), 1689–1699.
40. 40 Sequist, LV, Rolfe, L, Allen, AR, Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 373 (2015), 578–579.
41. 41 Jänne, PA, Shaw, AT, Pereira, JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14 (2013), 38–47.
42. 42 Mazières, J, Gandara, SR, Leighl, NB, et al. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed in a phase 1/1B trial involving KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): efficacy and biomarker results. J Thorac Oncol, 8, 2013, 2922.
43. 43 Marchetti, A, Felicioni, L, Malatesta, S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 29 (2011), 3574–3579.
44. 44 Paik, PK, Arcila, ME, Fara, M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29 (2011), 2046–2051.
45. 45 Hyman, DM, Puzanov, I, Subbiah, V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373 (2015), 726–736.
46. 46 Planchard, D, Kim, TM, Mazieres, J, et al. Dabrafenib in patients with BRAFV600E -positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol 17 (2016), 642–650.
47. 47 Mazières, J, Peters, S, Lepage, B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 31 (2013), 1997–2003.
48. 48 Kris, MG, Camidge, DR, Giaccone, G, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol 26 (2015), 1421–1427.
49. 49 Sadiq, AA, Salgia, R, MET as a possible target for non-small-cell lung cancer. J Clin Oncol 31 (2013), 1089–1096.
50. 50 Paik, PK, Drilon, A, Fan, PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 5 (2015), 842–849.
51. 51 Shaw, AT, Yeap, BY, Mino-Kenudson, M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27 (2009), 4247–4253.
52. 52 Katayama, R, Lovly, CM, Shaw, AT, Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 21 (2015), 2227–2235.
53. 53 Gainor, JF, Varghese, AM, Ou, SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 19 (2013), 4273–4281.
54. 54 Shaw, AT, Kim, DW, Nakagawa, K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368 (2013), 2385–2394.
55. 55 Solomon, BJ, Mok, T, Kim, DW, et al. Firstline crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371 (2014), 2167–2177.
56. 56 Shaw, AT, Kim, DW, Mehra, R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370 (2014), 1189–1197.
57. 57 Gadgeel, SM, Gandhi, L, Riely, GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15 (2014), 1119–1128.
58. 58 Gettinger, S, Bazhenova, L, Salgia, R, et al. ALK Inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC): updated efficacy and safety data. Ann Oncol 25 (2014), iv426–iv470.
59. 59 Zou, HY, Li, Q, Engstrom, LD, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci USA 112 (2015), 3493–3498.
60. 60 Bergethon, K, Shaw, AT, Ou, SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30 (2012), 863–870.
61. 61 Shaw, AT, Ou, SH, Bang, YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371 (2014), 1963–1971.
62. 62 Boyle, TA, Masago, K, Ellison, KE, Yatabe, Y, Hirsch, FR, ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin Lung Cancer 16 (2015), 106–111.
63. 63 Mazières, J, Zalcman, G, Crinò, L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 33 (2015), 992–999.
64. 64 Awad, MM, Katayama, R, McTigue, M, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 368 (2013), 2395–2401.
65. 65 Rolfo, C, Passiglia, F, Castiglia, M, et al. ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it. Transl Lung Cancer Res 3 (2014), 250–261.
66. 66 Califano, R, Abidin, A, Tariq, NU, Economopoulou, P, Metro, G, Mountzios, G, Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. Cancer Treat Rev 41 (2015), 401–411.
67. 67 Drilon, A, Wang, L, Hasanovic, A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3 (2013), 630–635.
68. 68 Drilon, A, Sima, CS, Somwar, R, et al. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. J Clin Oncol, 33, 2015, 8007 (abstr).
69. 69 Doebele, RC, Davis, LE, Vaishnavi, A, et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov 5 (2015), 1049–1057.
70. 70 Camidge, DR, Ou, SD, Shapiro, G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol, 32, 2014, 8001 (abstr).
71. 71 Shigematsu, H, Lin, L, Takahashi, T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005), 339–346.
72. 72 Mitsudomi, T, Morita, S, Yatabe, Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11 (2010), 121–128.
73. 73 Sequist, LV, Yang, JC, Yamamoto, N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31 (2013), 3327–3334.
74. 74 Wu, Y-L, Zhou, C, Liam, CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 26 (2015), 1883–1889.
75. 75 Yang, JC, Sequist, LV, Geater, SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 16 (2015), 830–838.
76. 76 Sequist, LV, Waltman, BA, Dias-Santagata, D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 3, 2011, 75ra26.
77. 77 Piotrowska, Z, Niederst, MJ, Karlovich, CA, et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov 5 (2015), 713–722.
78. 78 Park, K, Lee, JS, Lee, KH, et al. Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI). J Clin Oncol, 33, 2015, 8084 (abstr).
79. 79 Yang, JJ, Chen, HJ, Yan, HH, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer 79 (2013), 33–39.
80. 80 Weickhardt, AJ, Scheier, B, Burke, JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 7 (2012), 1807–1814.
81. 81 Park, K, Yu, CJ, Kim, SW, et al. First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation–positive non–small-cell lung cancer: the ASPIRATION study. JAMA Oncol 2 (2016), 305–312.
82. 82 Soria, JC, Wu, Y-L, Nakagawa, K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol 16 (2015), 990–998.
83. 83 Thress, KS, Paweletz, CP, Felip, E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21 (2015), 560–562.
84. 84 Ercan, D, Choi, HG, Yun, CH, et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res 21 (2015), 3913–3923.
85. 85 Mok, T, Wu, Y-L, Lee, JS, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 21 (2015), 3196–3203.
86. 86 Oxnard, GR, Paweletz, CP, Kuang, Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20 (2014), 1698–1705.
87. 87 Karachaliou, N, Mayo-de las Casas, C, Queralt, C, et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol 1 (2015), 149–157.
88. 88 Wu, Y-L, Lee, JS, Thongprasert, S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol 14 (2013), 777–786.
89. 89 Seto, T, Kato, T, Nishio, M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 15 (2014), 1236–1244.
90. 90 Stahel, RA, Dafni, U, Gautschi, O, et al. A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. Eur J Cancer 51 (2015), S711–S712.
91. 91 Zeng, Q, Wang, J, Cheng, Z, et al. Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor. J Med Chem 58 (2015), 8200–8215.
92. 92 Soda, M, Choi, YL, Enomoto, M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007), 561–566.
93. 93 Rikova, K, Guo, A, Zeng, Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131 (2007), 1190–1203.
94. 94 Kwak, EL, Bang, YJ, Camidge, DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363 (2010), 1693–1703.
95. 95 Camidge, DR, Bang, YJ, Kwak, EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13 (2012), 1011–1019.
96. 96 Kim, D-W, Ahn, M-J, Shi, Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer. J Clin Oncol, 30, 2012, 7533 (abstr).
97. 97 Costa, DB, Shaw, AT, Ou, SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged nonsmall-cell lung cancer and brain metastases. J Clin Oncol 33 (2015), 1881–1888.
98. 98 Doebele, RC, Pilling, AB, Aisner, DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18 (2012), 1472–1482.
99. 99 Friboulet, L, Li, N, Katayama, R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4 (2014), 662–673.
100. 100 Mok, T, Spigel, D, Felip, E, et al. ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol, 33, 2015, 8059 (abstr).
101. 101 Shaw, AT, Gandhi, L, Gadgeel, S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17 (2016), 234–242.
102. 102 Felip, E, Orlov, S, Park, K, et al. ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol, 33, 2015, 8060 (abstr).
103. 103 Seto, T, Kiura, K, Nishio, M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 14 (2013), 590–598.
104. 104 Nokihara, H, Hida, T, Kondo, M, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. J Clin Oncol, 34, 2016, 9008 (abstr).
105. 105 Wang, R, Hu, H, Pan, Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 30 (2012), 4352–4359.
106. 106 Michels, S, Scheel, AH, Scheffler, M, et al. Clinicopathological characteristics of RET rearranged lung cancer in European patients. J Thorac Oncol 11 (2016), 122–127.
107. 107 Scagliotti, G, von Pawel, J, Novello, S, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 33 (2015), 2667–2674.
108. 108 Spigel, DR, Edelman, MJ, O'Byrne, K, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicentre, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol, 32, 2014, 8000 (abstr).
109. 109 Planchard, D, Groen, HJM, Kim, TM, et al. Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAFV600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). J Clin Oncol, 33, 2015, 8006 (abstr).
110. 110 Dearden, S, Stevens, J, Wu, Y-L, Blowers, D, Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 24 (2013), 2371–2376.
111. 111 Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489 (2012), 519–525.
112. 112 Weiss, J, Sos, ML, Seidel, D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med, 2, 2010, 62ra93.
113. 113 Hammerman, PS, Sos, ML, Ramos, AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1 (2011), 78–89.
114. 114 Bunn, PA Jr, Minna, J, Augustyn, A, et al. Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes?. J Thorac Oncol 4 (2016), 453–474.
115. 115 Pietanza, MC, Byers, LA, Minna, JD, Small cell lung cancer: will recent progress lead to improved outcomes?. Clin Cancer Res 21 (2015), 2244–2255.
116. 116 Almquist, D, Mosalpuria, K, Ganti, AK, Multimodality therapy for limited-stage small-cell lung cancer. J Oncol Pract 12 (2016), 111–117.
117. 117 Garon, EB, Ciuleanu, TE, Arrieta, O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384 (2014), 665–673.
118. 118 Reck, M, Kaiser, R, Mellemgaard, A, et al., LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15 (2014), 143–155.
119. 119 Committee for Medicinal Products for Human Use. Summary of opinion: Portrazza, Dec 17, 2015, European Medicines Agency, London http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003886/WC500199044.pdf (accessed March 6, 2016).
120. 120 Forde, PM, Kelly, RJ, Brahmer, JR, New strategies in lung cancer: translating immunotherapy into clinical practice. Clin Cancer Res 20 (2014), 1067–1073.
121. 121 Vansteenkiste, JF, Cho, BC, Vanakesa, T, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 17 (2016), 822–835.
122. 122 Quoix, E, Lena, H, Losonczy, G, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol 17 (2016), 212–223.
123. 123 Pardoll, DM, The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
124. 124 Postow, M, Callahan, MK, Woldchok, JD, Immune checkpoint blockade in cancer therapy. J Clin Oncol 33 (2015), 1974–1983.
125. 125 Brahmer, J, Reckamp, KL, Baas, P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
126. 126 Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
127. 127 Herbst, R, Baas, P, Kim, DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2015), 1540–1550.
128. 128 Fehrenbacher, L, Spira, A, Ballinger, M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
129. 129 Rizvi, N, Brahmer, JR, Ou, SH, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol, 33, 2015, 8032 (abstr).
130. 130 Gulley, JL, Spigel, D, Chandler, JC, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. J Clin Oncol, 33, 2015, 8034 (abstr).
131. 131 Gettinger, SN, Horn, L, Gandhi, L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33 (2015), 2004–2012.
132. 132 Garon, EB, Rizvi, NA, Hui, R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
133. 133 Soria, JC, Fløtten, Ø, Horn, L, et al. Efficacy and safety of pembrolizumab (Pembro; MK-3475) for patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC) enrolled in KEYNOTE-001. Ann Oncol, 26, 2015, 33LBA (abstr).
134. 134 Herbst, RS, Soria, JC, Kowanetz, M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
135. 135 Merck's KEYTRUDA (pembrolizumab) demonstrates superior progression-free and overall survival compared to chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer [news release], June 16, 2016, Merck, Kenilworth, NJ http://www.mercknewsroom.com/news-release/oncology-newsroom/mercks-keytruda%20pembrolizumab-demonstrates-superior-progression-free (accessed June 18, 2016).
136. 136 Kerr, KM, Hirsch, FR, Programmed Death Ligand 1 immunohistochemistry: friend or foe?. Arch Pathol Lab Med 140 (2016), 326–331.
137. 137 Besse, B, Johnson, M, Janne, PA, et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Eur J Cancer 51 (2015), S717–S718.
138. 138 Antonia, SJ, Bendel, JC, Taylor, MH, et al. Phase I/II study of nivolumab with or without ipilimumab for the treatment of recurrent small cell lung cancer (SCLC): CA209.032. J Clin Oncol, 33, 2015, 7503 (abstr).
139. 139 Alley EW, Schellens JH, Santoro A, et al. Single-agent pembrolizumab for patients with malignant pleural mesothelioma (MPM). IASLC 16th World Conference on Lung Cancer; Denver, CO, USA; Sept 6–9, 2015. Abstract 3011.
140. 140 Ramalingam, SS, Owonikoko, TK, Khuri, FR, Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 61 (2011), 91–112.
141. 141 Masters, GA, Temin, S, Azzoli, CG, et al. Systemic therapy for stage iv non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33 (2015), 3488–3515.
142. 142 Ciuleanu, T, Brodowicz, T, Zielinski, C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374 (2009), 1432–1440.
143. 143 Cappuzzo, F, Ciuleanu, T, Stelmakh, L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11 (2010), 521–529.
144. 144 Paz-Ares, LG, de Marinis, F, Dediu, M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer. J Clin Oncol 31 (2013), 2895–2902.
145. 145 Westeel, V, Quoix, E, Moro-Sibilot, D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 97 (2005), 499–506.
146. 146 Fidias, PM, Dakhil, SR, Lyss, AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27 (2009), 591–598.
147. 147 Brodowicz, T, Krzakowski, M, Zwitter, M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52 (2006), 155–163.
148. 148 Belani, CP, Waterhouse, DM, Ghazal, HH, et al. Randomized trial of gemcitabine-carboplatin (G-Cb) therapy followed by gemcitabine (G) maintenance or best supportive care (BSC) in advanced NSCLC. J Clin Oncol, 28, 2010, 7506 (abstr).
149. 149 Perol, M, Chouaid, C, Perol, D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 30 (2012), 3516–3524.
150. 150 Zhang, X, Zang, J, Xu, J, et al. Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis. Chest 140 (2011), 117–126.
151. 151 Behera, M, Owonikoko, TK, Chen, Z, et al. Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis. Lung Cancer 77 (2012), 331–338.
152. 152 Zhao, H, Fan, Y, Ma, S, et al. Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804). J Thorac Oncol 10 (2015), 655–664.